Not when they've just spent 229mUS to get azer-cell. If ALA-101 were even on par, or outperforming what azer-cell can do, then it wouldnt be a good look. If the data was bad, wouldnt they want to release that info to market to knock down one of their direct competitors?
To me, it seems like two different companies, moving in two different directions, IMU staying with CAR-T and ALA sticking with iNKT tech.
News: IMU Arovella Therapeutics Gives ALA-101 And Oncarlytics Collaboration Update, page-21
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.002(4.00%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 5.0¢ | 5.0¢ | 4.7¢ | $2.298M | 47.86M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1925982 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 3452098 | 12 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |